Clinical Trials Logo

Filter by:
NCT ID: NCT04851418 Recruiting - Clinical trials for Coronary Artery Disease

Pre-hOspital Evaluation of Chest Pain Patients With sUspected Non ST-segment eLevation myocARdial Infarction Using the HEART-score With a Troponin Point-of-care Test

POPular HEART
Start date: September 1, 2020
Phase:
Study type: Observational

Overcrowding in the emergency department is an increasing problem in hospitals worldwide. Point-of-care Troponin (POC cTn) testing combined with a well investigated risk stratification tool (HEART-score) used in the ambulance may contribute to more rapidly diagnostics of ruling in or ruling out myocardial infarctions (MI) and subsequently reduce unnecessary hospital admissions, total admission time and costs. However, the applicability of the POC cTn and the HEART-score in the pre-hospital setting remains unclear. This study will evaluate this applicability.

NCT ID: NCT04851041 Recruiting - Glucose Metabolism Clinical Trials

Effects of a Potato-based Food Pattern vs a Rice / Pasta-based Food Pattern on Cardiometabolic Health

LoPoCardio
Start date: March 3, 2021
Phase: N/A
Study type: Interventional

The researchers investigate the effect of long-term (12-weeks) consumption of diets rich in boiled potatoes versus those rich in rice or pasta on established cardiovascular risk parameters. These carbohydrate sources will be part of a recommended healthy dietary pattern to mimic as closely as possible current dietary guidelines, facilitating the implementation of the outcomes.

NCT ID: NCT04850339 Recruiting - Healthy Clinical Trials

First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers

Start date: December 21, 2020
Phase: Phase 1
Study type: Interventional

This is an adaptive, randomised, double-blind, single-centre, placebo-controlled phase I, First in Human study designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous dosing of ANXV in healthy male subjects.

NCT ID: NCT04850118 Not yet recruiting - Clinical trials for X-Linked Retinitis Pigmentosa

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Start date: August 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501) to an untreated control group in male patients with X-linked retinitis pigmentosa caused by RPGR mutations.

NCT ID: NCT04849390 Not yet recruiting - Clinical trials for Eosinophilic Esophagitis

A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis

Start date: April 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled, double-blind trial to evaluate the efficacy, tolerability, and safety of ESO-101 in adult patients with active eosinophilic esophagitis (EoE). Patients will be screened at 2 visits (Visit 1 and Visit 2) during which their eligibility will be assessed based on endoscopy-independent criteria (Visit 1) and based on the histologic assessment of esophageal biopsy samples taken during the screening endoscopy (Visit 2). Eligible patients will be randomized 2:1 to once-daily treatment with ESO-101 or placebo and treated for 28 days starting on Day 0. Further clinic visits will be performed at Day 14 (Visit 4) and Day 28 (Visit 5, end of treatment) to assess the efficacy, tolerability, and safety. In addition, a safety follow-up call will be scheduled 2 weeks after the end of treatment (Day 42, Visit 6).

NCT ID: NCT04848558 Not yet recruiting - Healthy Clinical Trials

A Study of Nipocalimab in Healthy Male and Female Participants

Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of nipocalimab following subcutaneous (SC) administration compared with intravenous (IV) administration in healthy participants.

NCT ID: NCT04848077 Not yet recruiting - Parkinson Disease Clinical Trials

STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease

STEPWISE
Start date: April 2021
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether a smartphone app can increase physical activity in patients with Parkinson's Disease in daily life for a long period of time (12 months).

NCT ID: NCT04847895 Completed - Clinical trials for Neovascular (Wet) Age-related Macular Degeneration

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

PACIFIC
Start date: June 1, 2015
Phase:
Study type: Observational

This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.

NCT ID: NCT04847622 Recruiting - Covid19 Clinical Trials

Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

909REM
Start date: February 1, 2021
Phase:
Study type: Observational

This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases from up to 20 participating study sites who meet all eligibility criteria will be included in the analysis. Deidentified data will be extracted from electronic medical record (EMR) databases, clinical registries, case series or additional sources from participating sites and countries, and then entered into a structured e-CRF system. addition, each site/country will be surveyed to determine the local standard of care therapy for COVID-19 infection and to determine if standard protocols were/are in place for the use of Remdesivir and if/how the protocols changed over time.

NCT ID: NCT04846036 Recruiting - Clinical trials for Mitochondrial Diseases

The KHENERGYC Study

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This a randomized placebo controlled, double-blind phase II study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children (from birth to 17 years) with genetically confirmed mitochondrial disease of which the gene defect is known to decrease one or more oxidative phosphorylation system enzymes and who suffer from motor symptoms ("KHENERGYC").